Clinical Efficacy Of Qushi Tongluo Prescription In The Treatment Of Drug-resistant Mycoplasma Pneumoniae Pneumonia In Children

Objective:To monitor the clinical effectiveness of Qushi Tongluo prescription for the treatment of drug-resistant Mycoplasma pneumoniae pneumonia in children and to provide a reference for the clinical treatment of drug-resistant Mycoplasma pneumoniae pneumonia.Methods:The cases were all from the pediatric ward of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine between November 2021 and December 2022.Based on the diagnosis and the use of standard macrolide antibiotics,the treatment group received granules of the Qushi Tongluo prescription orally,while the control group received Drug simulants orally for 7 days.To observe the changes in symptoms,signs,CRP,immunoglobulins,and T-lymphocyte subsets before and after treatment in both groups.And statistical analysis was performed using SPSS25.0.Results:1.Clinical efficacy:1.Clinical efficacy:The healing rate in the treatment group was 56.67%and in the control group 24.14%.（P<0.05）.Length of stay in hospital and time to complete fever reduction was shorter in the treatment group than in the control group（P<0.05）.No statistically significant difference in time to onset of cough and sputum between the two groups（P>0.05）.Symptoms and signs and concurrent evidence scores decreased in both groups after treatment compared to pre-treatment（P<0.05）.The treatment group outperformed the control group in improving signs and symptoms such as lung rales,nausea and vomiting,redness and swelling of the throat,runny nose,dullness,irregular bowel movements and yellowish urine（P<0.05）.2.Laboratory results:No statistically significant differences in CRP,immunoglobulin and T cell subpopulation levels between the two groups before treatment（P>0.05）.The treatment group outperformed the control group in terms of reducing CRP levels（P<0.05）.Before treatment,Ig A was lower than normal in both groups,while Ig M and Ig G were at normal levels;after treatment,Ig A,Ig M and Ig G levels increased in both groups,all better than before treatment（P<0.05）;In the treatment group,Ig A levels were higher than in the control group（P<0.05）;No significant difference in Ig M and Ig G elevation between the two groups（P>0.05）.CD₃⁺,CD₄⁺and CD₄⁺/CD₈⁺levels were lower than normal in both groups before treatment（P>0.05）;After treatment,CD₃⁺,CD₄⁺and CD₄⁺/CD₈⁺were elevated in both groups,better than before treatment（P<0.05）;No statistically significant difference in CD₈⁺before and after treatment（P>0.05）.Elevated CD₄⁺and CD₄⁺/CD₈⁺levels were better in the treatment group than in the control group（P<0.05）.No significant difference in elevated CD₃⁺levels between the two groups（P>0.05）.3.Safety evaluation:The study included 59 children without liver or kidney problems and electrocardiograms before and after treatment.Conclusions:Qushi Tongluo prescription combined with macrolide antibioticshas has significant clinical efficacy in the treatment of drug-resistant mycoplasma pneumoniae pneumonia（damp-heat closed lung evidence）.It can improve the recovery rate,shorten the hospitalization time and fever reduction time,promote the absorption of rales in the lungs,improve the symptoms of nausea and vomiting,red and swollen throat,runny nose,dullness,irregular bowel movements and small yellow urine,and regulate the immune function with good safety.